Palisade Bio Reports Improved Quarterly Losses

Palisade Bio, Inc. ( (PALI) ) has released its Q1 earnings. Here is a breakdown of the information Palisade Bio, Inc. presented to its investors.

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company based in Carlsbad, California, focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, with a lead product candidate targeting inflammatory bowel disease. In its latest earnings report for the quarter ended March 31, 2025, Palisade Bio reported a net loss of $2.23 million, a significant improvement from the $3.53 million loss in the same period last year. The company’s operating expenses decreased to $2.31 million from $3.67 million, primarily due to reduced research and development costs. Palisade Bio’s cash and cash equivalents stood at $7.23 million, down from $9.82 million at the end of 2024, reflecting ongoing investments in product development. The company continues to focus on advancing its lead candidate, PALI-2108, and has entered into strategic collaborations, including a significant license agreement with Giiant Pharma. Looking ahead, Palisade Bio remains committed to its development pipeline, although it acknowledges the challenges of achieving profitability and the need for additional funding to support its operations.